Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban for stroke prevention in device-detected subclinical atrial fibrillation
NL-OMON52976Phase 4Completed
- Sponsor
- Population Health Research Institute
- Start
- Nov 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of apixaban and aspirin in Atrial fibrillation (AFib), sponsored by Population Health Research Institute. Primary endpoints: Composite of stroke and systemic embolism and Major bleeding. Started Nov 2016; status: completed.
02
Drugs
apixabanaspirin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NL-OMON52976.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52976.